XNYS
PRGO
Market cap2.18bUSD
Oct 30, Last price
15.78USD
1D
-0.75%
1Q
56.08%
Jan 2017
-81.04%
Name
Perrigo Company PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Related entities
Subsidiaries (9)
GALPHARM INTERNATIONAL LIMITED
OMEGA PHARMA BELGIUM
OMEGA PHARMA INVEST NV
OMEGA PHARMA NV
PERRIGO CAPITAL
PERRIGO FINANCE UNLIMITED COMPANY
Perrigo Investments, LLC
PERRIGO UK ACQUISITION LIMITED
WRAFTON LABORATORIES LIMITED
Key people
Patrick Lockwood-Taylor
President, Chief Executive Officer, Director · since 2023
Eduardo Bezerra
Chief Financial Officer, Executive Vice President · since 2022
David Ball
Executive Vice President, Chief Brand and Digital Officer · since 2024
Roberto Khoury
Executive Vice President, Chief Commercial Officer · since 2025
Abigail Lennox
Executive Vice President, Chief Scientific Officer · since 2025
Robert Willis
Chief Human Resources Officer, Executive Vice President · since 2019
Matt Winterman
Executive Vice President - Product Supply, Operations Strategy and Transformation Officer · since 2025
Charles Atkinson
Executive Vice President, General Counsel, Company Secretary · since 2024
Independent Director · since 2017
Orlando Ashford
Independent Chairman of the Board · since 2022
Julia Brown
Independent Director · since 2023
Kevin Egan
Independent Director · since 2025
Independent Director · since 2017
Independent Director · since 2017
Independent Director · since 2022
Independent Director · since 2014
Independent Director · since 2016
Independent Director · since 2025
Headquarters & legal address
THE SHARP BUILDING
HOGAN PLACE
DUBLIN 2
DUBLIN, D D02 TY74
IE
HOGAN PLACE
DUBLIN 2
DUBLIN, D D02 TY74
IE
Previous name
BLISFONT LIMITED
Previous name
PERRIGO COMPANY LIMITE
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||